Document:

EX-10.18

 Exhibit 10.18 

TRIVASCULAR 
 March 14, 2013 

Kimberley Elting 
 Dear Kimberley: 

I am pleased to offer you the position of General Counsel and Vice President, Corporate Affairs at TriVascular, Inc. (“TriVascular”), reporting to me
as TriVascular’s President and CEO. 
 Pay and Benefits. The salary for this position is $22,917.00 per month ($275,000 annually) less
all applicable deductions, paid biweekly in accordance with TriVascular’s standard payroll practice. You will be entitled to the TriVascular benefits package outlined on the attached sheet. TriVascular reserves the right to change or
discontinue its employee benefits from time to time. A target milestone-based bonus of 30% of annual salary will be instituted on a calendar year basis. In addition, you will receive a one-time signing bonus of $10,000, less applicable deductions,
payable within thirty days of the commencement of employment. 
 Personnel Policies. Like all employees of TriVascular, you will be expected
to comply with the rules, procedures, and policies of TriVascular as adopted from time to time During the time that you are employed by TriVascular, unless you receive prior approval from me, you will not directly or indirectly own an interest in,
join, operate, control or participate in, or be connected as an officer, employee, agent, independent contractor, consultant, member, partner or principal with any other entity or person engaged in developing, providing, soliciting orders for,
selling, distributing or marketing services or products that directly or indirectly compete with those provided by TriVascular. 
 License to Practice
Law. You represent and warrant that you are currently licensed to practice law in the State of Texas (Bar Card Number 24003727), and that you are in good disciplinary standing with the State Bar of Texas. While employed by TriVascular in the
role of General Counsel or any other role requiring the practice of law, you will maintain a valid license to practice. You will immediately report to TriVascular any bar disciplinary action against you and/or loss of your license to practice.
TriVascular will reimburse you for state bar licensing fees and continuing legal education course/credit fees required to maintain licensure, and membership fees for professional legal associations. 

At Will Employment. Your employment with TriVascular is “at will”. This means that you may leave TriVascular at any time, for any
reason, with or without notice and with or without cause and that TriVascular may terminate your employment at any time for any reasons, or no reason, with or without notice and with or without cause. The at-will nature of your employment can only
be changed in a writing signed by you and by TriVascular. 
 Indemnification. TriVascular will provide you with indemnification in accordance
with the enclosed Indemnification Agreement. 
 Change-in-Control Benefits. [Superseded by Key Employee Change of Control and Severance
Payment Plan] 

  
 1 

 TRIVASCULAR 

Stock Option. Subject to approval by the Board of Directors, it is our intention to offer you the opportunity to participate in our TriVascular
Stock Option Plan (the “SOP”). Pursuant to the SOP, TriVascular would grant you an incentive stock option to purchase 2,500,000 shares of common stock of TriVascular at a price to be approved by the Board. This grant would be made in a
Stock Option Agreement that would contain the complete terms of the grant, and your execution of the Stock Option Agreement is a condition of the grant. 

Normal Vesting Schedule. Your option described in the previous paragraph (the “Offer Letter ISO”) can be
exercised only to the extent that it is vested. Initially none of the Offer Letter ISO will be vested, but it will become vested as to 625,000 shares of TriVascular common stock on the one-year anniversary of the vesting start date, which is
expected to be the date you commence employment with TriVascular. The Offer Letter ISO will become vested as to the remaining 1,875,000 shares of TriVascular common stock at a rate of 52,083 shares per month for a period of thirty-six months,
commencing with the thirteenth calendar month after the vesting start date. In accordance with the Severance Provisions, all unvested Offer Letter ISO shares will accelerate in the event of a Change in Control. 

Vesting ceases immediately in the event of termination of your employment. Unless and until an initial public offering takes place, stock that is issued to
you upon exercise of vested option rights under the Offer Letter ISO will be subject to substantial restrictions on transfer, including a right of first refusal applicable to some transfers and an option to purchase applicable to others, subject to
limited exceptions for transfers to family members. 
 Arbitration. Any and all disputes related to this offer or arising out of or related to
your employment with TriVascular or any of its agents, officers, directors, employees or affiliated entities (each of whom is designated an intended beneficiary of this agreement to arbitrate) will be submitted to and resolved through final and
binding arbitration. The arbitration will be instead of any civil litigation; this means that TriVascular and you are each waiving any right to a jury trial. The arbitrator’s decision shall be final and binding to the fullest extent permitted
by law, and will be enforceable by any court having jurisdiction thereof. The disputes subject to arbitration include, but are not limited to, any claims for breach of contract, breach of the enclosed Covenant Not to Compete, discrimination or
harassment, or violation of any other federal, state or local law or regulation. Arbitration is to be conducted in Dallas, Texas, in accordance with the rules and regulations of the American Arbitration Association (“AAA”) using its
National Employment Dispute Resolution Rules, including procedures for discovery sufficient to adequately arbitrate any statutory claims, as determined by the arbitrator. The arbitration filing fee expenses shall be borne according to the rules of
AAA, except that TriVascular will pay all types of costs that are unique to arbitration, such as the arbitrator’s fees. The foregoing agreement to arbitrate does not prevent either you or TriVascular from filing a court action in aid of
arbitration (such as seeking preliminary injunctive relief pending final resolution of a matter in arbitration). By signing this offer letter, you consent to the jurisdiction of the federal and state courts located in Dallas County, Texas for any
such court actions or other proceedings ancillary to arbitration (such as a proceeding to compel arbitration or to confirm or vacate an arbitration award). 

Texas Office. TriVascular acknowledges that your primary office will be located in Dallas, Texas, and agrees to provide IT equipment necessary
to facilitate effective communication including, laptop computer, printer and telephone land line. In addition, TriVascular will reimburse you for cell phone and iPad monthly charges, and travel to and from Santa Rosa, and business class upgrades
where available. 

  
 2 

 TRIVASCULAR 

Other Terms and Conditions. This offer is contingent upon your ability to provide appropriate documentation within three (3) days after
your start date establishing that you are legally authorized to work in the United States. In addition, this offer of employment is contingent upon your signing of the enclosed form of Employee Invention and Confidential Information Agreement,
Covenant Not to Compete, and Indemnification Agreement and any other documents customarily executed at the time of starting employment, and is further contingent upon TriVascular’s written acceptance (in its discretion) of the information you
disclose in the Employee Invention and Confidential Information Agreement. You should understand that TriVascular is hiring you for your skills and abilities and not for any tangible or intangible items or proprietary information obtained by you
from any of your former employers. By accepting employment with TriVascular, you agree that you will not, in the performance of your duties at TriVascular, utilize any or disclose any trade secrets, confidential, or proprietary information of former
employers and that you will neither take with you any tangible items containing any such information, such as drawings or reports, when you leave your current employer, nor bring such items into the workplace at TriVascular. 

This offer letter, including the enclosed Employee Invention and Confidential Information Agreement, Covenant Not to Compete, and Indemnification Agreement
sets forth the entire agreement between you and TriVascular concerning the terms and conditions of your employment, and neither you nor TriVascular will be bound by any condition or understanding with respect to your employment other than that
expressly provided in this letter. The offer letter supersedes and replaces all previous agreements or understandings regarding the terms of your employment and can only be amended in a writing signed by TriVascular and you. 

It is my understanding that you would be available for employment with TriVascular no later than March 31, 2013. Please indicate your acceptance of this
offer by signing and returning one copy of this letter to me on or before March 22, 2013. This offer will expire on March 23, 2013. 
 I look
forward to welcoming you to the TriVascular team and am confident that the experience will be mutually rewarding and satisfying. 
  

	
	Sincerely,
	
	/s/ Christopher G. Chavez
	
	Christopher G. Chavez
	President & CEO
	TriVascular, Inc.

 I have read and understand the foregoing letter and accept employment with TriVascular as set forth above. 

 

					
	 /s/ Kimberley Elting
	 		 	 3/15/2013

	Kimberley Elting	 		 	Date

  
 3EX-10.19

 Exhibit 10.19 

TRIVASCULAR 
 October 4, 2009 

Mr. Vivek K. Jayaraman 
 Dear Vivek: 

I am pleased to offer you the position of Vice President, Commercial Operations (Global Marketing, International Sales and Business Development) at
TriVascular2, Inc. (“TriVascular2”), reporting to me as TriVascular2, Inc.’s President and CEO. 
 Pay and Benefits. The salary for
this position is $20,600 per month less all applicable deductions, paid biweekly in accordance with TriVascular2’s standard payroll practice. You will be entitled to the TriVascular2 benefits package outlined on the attached sheet. TriVascular2
reserves the right to change or discontinue its employee benefits from time to time. A target milestone-based bonus of up to 30% of annual salary will be instituted on a calendar year basis. In addition, should your real estate loan (estimated at
$150,000) from your current employer become due and payable as a result of your acceptance and commencement of employment at TriVascular2, you will be extended a loan in the same amount by TriVascular2. In addition, an allowance of up to $5,000 is
available to you for reimbursement of any legal and/or tax advice expenses you may incur in connection with your acceptance of the terms of this offer. In recognition of incentive payments you will be foregoing from your previous employer, we will
offer you an annual retention bonus over a four year period in the amount of $50,000 per year. 
 Personnel Policies. Like all employees of
TriVascular2, you will be expected to comply with the rules, procedures, and policies of TriVascular2 as adopted from time to time. During the time that you are employed by TriVascular2, unless you receive prior approval from one of the officers,
you will not directly or indirectly own (other than through any prior employment) an interest in, join, operate, control or participate in, or be connected as an officer, employee, agent, independent contractor, consultant, member, partner or
principal with any other entity or person engaged in developing, providing, soliciting orders for, selling, distributing or marketing services or products that directly or indirectly compete with those provided by TriVascular2. 

At Will Employment. Your employment with TriVascular2 is “at will”. This means that you may leave TriVascular2 at any time, for any reason,
with or without notice and with or without cause and that TriVascular2 may terminate your employment at any time, for any reason, or no reason, with or without notice and with or without cause. The at-will nature of your employment can only be
changed in a writing signed by you and by TriVascular2’s Chief Executive Officer. 
 Stock Option. Subject to approval by the Board of
Directors, it is our intention to offer you the opportunity to participate in our TriVascular2 Stock Option Plan (the “SOP”). Pursuant to the SOP, TriVascular2 would grant you an incentive stock option to purchase 1,000,000 shares of
common stock of TriVascular2 at a price to be approved by the Board, estimated at $0.21 per share. This grant would be made in a Stock Option Agreement that would contain the complete terms of the grant, and your execution of the Stock Option
Agreement is a condition of the grant. 

 TRIVASCULAR 

Normal Vesting Schedule. Your option described in the previous paragraph (the “Offer Letter ISO”) can be exercised only to the extent that it
is vested. Initially none of the Offer Letter ISO will be vested, but it will become vested as to 250,000 shares of TriVascular2 common stock on the one-year anniversary of the vesting start date, which is expected to be the date you commence
employment with TriVascular2. The Offer Letter ISO will become vested as to the remaining 750,000 shares of TriVascular2 common stock at a rate of 20,833 1/3 shares per month for a period of thirty-six months, commencing with the 13th calendar month
after the vesting start date. Vesting ceases immediately in the event of termination of your employment. Unless and until an initial public offering takes place, stock that is issued to you upon exercise of vested option rights under the Offer
Letter ISO will be subject to substantial restrictions on transfer, including a right of first refusal applicable to some transfers and an option to purchase applicable to others, subject to limited exceptions for transfers to family members. 

Arbitration. Any and all disputes related to this offer or arising out of or related to your employment with TriVascular2 will be submitted to and
resolved through final and binding arbitration. The arbitration will be instead of any civil litigation; this means that TriVascular2 and you are each waiving any right to a jury trial. The arbitrator’s decision shall be final and binding to
the fullest extent permitted by law, and will be enforceable by any court having jurisdiction thereof. The disputes subject to arbitration include, but are not limited to, any claims for breach of contract, discrimination or harassment, or violation
of any other federal, state or local law or regulation. Arbitration is to be conducted in Santa Rosa, California, in accordance with the rules and regulations of the America Arbitration Association (“AAA”) using the National Employment
Dispute Resolution Rules, including procedures for discovery sufficient to adequately arbitrate any statutory claims, as determined by the arbitrator. The arbitration filing fee expenses shall be borne according to the rules of AAA, except that
TriVascular2 will pay all types of costs that are unique to arbitration, such as the arbitrator’s fees. Notwithstanding the above, the parties agree that any claims either party has arising out of any Employee Invention and Confidential
Information Agreement or similar agreement you may sign with TriVascular2 are specifically excluded from this arbitration provision. This includes, for example only and without limitation, claims by TriVascular2 that you have disclosed or
misappropriated its trade secrets and/or claims by you that the Employee Invention and Confidential Information Agreement does not preclude you from working for a competitor of TriVascular2 or that you are the rightful owner of an invention you may
develop. 
 Other Terms and Conditions. This offer is contingent upon your ability to provide appropriate documentation within three (3) days
after your start date establishing that you are legally authorized to live and work in the United States. In addition, this offer of employment is contingent upon your signing of TriVascular2’s standard form of Employee Invention and
Confidential Information Agreement and any other documents customarily executed at the time of starting employment, and is further contingent upon TriVascular2’s 

  
 Page 2 of 3 

 TRIVASCULAR 

written acceptance (in its discretion) of the information you disclose in the Employee Invention and Confidential Information Agreement. You should understand
that TriVascular2 is hiring you for your skills and abilities and not for any tangible or intangible items or proprietary information obtained by you from any of your former employers. By accepting employment with TriVascular2, you agree that you
will not, in the performance of your duties at TriVascular2, utilize any or disclose any trade secrets, confidential, or proprietary information of former employers and that you will neither take with you any tangible items containing any such
information, such as drawings or reports, when you leave your current employer, nor bring such items into the workplace at TriVascular2. 
 This offer
letter, including the Employee Invention and Confidential Information Agreement, sets forth the entire agreement between you and TriVascular2 concerning the terms and conditions of your employment, and neither you nor TriVascular2 will be bound by
any condition or understanding with respect to your employment other than that expressly provided in this letter. The offer letter supersedes and replaces all previous agreements or understandings regarding the terms of your employment and can only
be amended in a writing signed by TriVascular2 and you. 
 It is my understanding that you will be available for employment with TriVascular2 no later than
October 19, 2009. Please indicate your acceptance of this offer by signing and returning one copy of this letter to me by fax (707) 541-3909 on or before October 9, 2009. This offer will expire on October 9, 2009. 

I look forward to welcoming you to the TriVascular2 team and am confident that the experience will be mutually rewarding and satisfying. 

 

	
	 Sincerely,

	
	 /s/ Michael V. Chobotov

	
	 Michael V. Chobotov, Ph.D.

	 President & Chief Executive Officer

	TriVascular, Inc.

 I have read and understand the foregoing letter and accept employment with TriVascular2 as set forth above. 

 

					
	 /s/ Vivek Jayaraman
	 		 	 10/6/2009

	Vivek K. Jayaraman	 		 	Date

  
 Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]